Globally, Ferring is taking on some of the most pervasive diseases of the digestive system that burden millions of people and their families. We’re curious and dedicated to following the science, conducting exhaustive research, and going where others may not.

Within our portfolio, we offer treatments for every stage of the patient’s journey with Crohn’s Disease, a debilitating chronic condition that causes inflammation of the digestive track¹.

As a proven leader in the field of microbiome research, Ferring is exploring the crucial link between the gut microbiome and human health to help people live better lives. Ferring offers the first FDA approved microbiota-based live biotherapeutic to prevent recurrence of C. difficile (C. diff) infection in adults following antibiotic treatment for recurrent C. diff infection.